Spinal cord injury (SCI) causes permanent dysfunction in the body movement and sensation. It is well known that recovery becomes more difficult as time passes from injury. Even with the power of stem cell transplant, it is still hard to cure the late phase of SCI. Despite the difficulty, majority of patients suffering from SCI are clinically late phase. Thus, overcoming the late phase of SCI is an important mission. CPTX is the structurally guided synthetic peptide that joins the pre-synaptic neurexin and the post-synaptic AMPA receptors (Suzuki, Sasakura et al., Science, (2020)). We previously showed that CPTX recovered the early phase of SCI in mouse model. CPTX restored the behavioral deficiency of Ataxia and Alzheimer’s mouse model as well. Therefore, CPTX is expected to be a promising medical agent to cure degenerated or injured CNS with novel concept (Salines, Science, 2020). To test if CPTX is effective to the late phase of SCI, we applied CPTX to the mice 4 or 6 weeks after SCI, which correspond to subacute or chronic phase of SCI patients, respectively. CPTX restored the late (chronic) -phase of SCI. CPTX injection activated the hind leg movement within a few days, which otherwise showed the permanently poor movement. At 2 weeks after injection, the effect of CPTX became maximum to the extent that some animals smoothly stepped. These results suggest that CPTX boost the dormant neural pathway into the active circuit. We are attempting the more robust recovery combined with rehabilitation.